Japan release of new breast cancer, diabetes drugs delayed over pricing

PharmaceuticalsEli Lily and Novo Nordisk treatments received approval at least 6 months agoTrump's drug price control policy could add pressure on Japan to raise prescription drug prices. (Source photos Nikkei)Nikkei staff writersAugust 23, 2026 05:49 JSTTOKYO -- The release of newly approved breast cancer and diabetes treatments by oversea drugmakers has been delayed in Japan as they continue to negotiate sales prices, highlighting foreign pharma's concern that Japan's state-mandated pricing tends to keep their product prices low.